

Disclaimer

The information contained in this document ("Document") has been prepared by Bio-Gene Technologies Limited (referred to as "Bio-Gene", "BGT" or the "Company").

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to invest in the Company or to acquire the Company's securities or assets. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation for investment, sale or purchase of any securities of business assets.

Offers of the Company's securities (if made) will be made in a prospectus which is expected to be lodged with the Australian Securities and Investments Commission ("ASIC") and ASX Limited and be available in or about mid September 2017 (which approximate date is indicative only and may change without notice). Anyone who is eligible and wishes to acquire securities of the Company will need to complete an application form that will accompany the Prospectus or apply by electronic means as will be specified in the prospectus. A copy of the prospectus will be available to be viewed on the Company's website (www.bio-gene.com.au) or it can be requested from the Company. Before deciding to acquire shares, you should read and consider the prospectus in its entirety and, if in any doubt, consult with your professional advisor.

Any reader should carry out and should rely on their own independent review, investigation, analysis and due diligence of the Company and its operations, business and assets. The information in this Document, is selective and does not purport to contain all the information that a reader may require to evaluate an opportunity, has not been independently verified by the Company or its advisors or any other person. No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of its officers, servants, agents or advisers (collectively "Disclosers") as to or in relation to the accuracy, reasonableness, completeness or reliability of this Document or any other written or oral information made available to any person or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects or returns in this Document are indicative only and are not and should not be relied upon as representations as to future matters. Any projections, management estimates or plans, prospects or returns are based on assumptions that may or may not prove to be correct. Any reader must make their own independent assessment and investigation of those assumptions.

Various statements in this Document constitute statements relating to intentions, future acts and events ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein. Disclosers do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future.

This Document is current as at 6 September 2017, however none of the Disclosers makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Nor do the Disclosers accept any responsibility to inform any reader of any matter arising or coming to its attention after this date.

The Disclosers do not undertake any obligation to provide any reader with access to any additional information or to correct any inaccuracies herein which may become apparent, and they reserve the right, without advance notice, to change the procedure for the sale of all or any part of the Company's assets or terminate the sale process and/or negotiations at any time prior to signing of any binding agreement. The issue of this Document shall not be taken as any form of commitment on the part of the Company to proceed with any transaction.

Provision of this Document and any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company do not constitute, and are not to be taken as constituting, the giving of investment or financial product advice to any person. Each person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice. Each person should note that the value of investments can go down as well as up and that the return on investments may vary.

This Document must not be copied, reproduced, distributed or passed to others at any time without the prior written consent of the Company.

This Document (or any part thereof) must not be brought into or accessed from any jurisdiction in which it is not lawful to do so.

To the fullest extent permitted by law, the Disclosers will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Disclosers becomes aware or any errors in or omissions from this Document.

The Global Problem of Pest Control

The Ag-Chem industry is seeking new & safer chemistry as global resistance continues to worsen



Pest Resistance

Pests are rapidly developing resistance to current insecticides



Environmental Impact

Public outrage at incumbent products' toxic impact on bees & other beneficial insects



Crop Losses

Insects destroy up to 26% of global crop production, reducing food availability, & increasing cost¹



Grain Losses

Storage pests can cause 25% - 70% loss in stored grain²



Vector-borne Diseases

Cause 17% of global illness & disability eg Malaria,

Dengue fever & Zika virus³




Consumer Products


Consumers are demanding natural insecticide products

In recent years the problem has worsened

Increasing number of resistant species



New insecticides are increasingly elusive



New compounds must demonstrate multiple qualities



Compound must be effective, either alone or in combination with incumbent insecticides, in controlling pests Safe Chemistry

New 'soft chemistries'
are required,
which don't
adversely impact
the environment
or beneficial
insects (e.g. bees)

Novel Mode of Action

Compounds must have a novel Mode of Action (MoA) to existing chemistries to be effective in controlling resistant pests

Scalability

Technology must be able to be produced at a commercial cost and volume

Bio-Gene's technology addresses these needs



Data shows Flavocide™
& Qcide™ are highly
effective for controlling
resistant pests across:

- Crop Protection
 Grain Storage
- 2) Public Health
- 3) Consumer Products



Trials show relatively low toxicity to bees & other beneficial insects

Tox studies to date indicate no observable adverse effects to mammals



Bio-Gene's compounds operate via a novel Mode of Action, which addresses pest resistance



CSIRO collaboration has refined production to be commercially viable

Bio-Gene has two unique compounds



Qcide™

Natural Compound

Extract of an Australian eucalypt: 'Gypmie Messmate'

Qcide™ is well suited to applications in consumer products, along with public health & crop protection where a natural product is preferred



Flavocide™

Nature Id<mark>entical</mark> Compound

A chemical process is used to produce a 'synthetic copy' of the compound that can be mass produced

Well suited for broad & larger verticals:

- 1) Crop Protection
- 2) Public Health

Well-defined pathway to commercialisation



Testing & Data Generation

Create suite of trial data & IP relating to efficacy, toxicity, mode of action and manufacturing

Introductory Commercial Discussions Globally

Present Ric Cone to major Ag Chem, Covernment Age

Present Bio-Gene to major Ag-Chem, Government Agencies, NGO's & Philanthropic Organisations

Evaluation Partnerships

Establish evaluation partnerships, to determine specific market applications

Commercial Deals

Progress evaluation partnerships to a commercial deal

Bio-Gene has delivered on multiple milestones in 2018



Significant Suite of Trial Data for Proof of Concept
Efficacy Testing



Toxicology Studies to Support Registration



Multiple Partnership
Discussions



Expanded Knowledge of Mode of Action



Strengthened Intellectual Property



Improved
Manufacturing
Capability



Appointed Expert
Advisors

Financial Overview

Strong Cash Position

BGT has a well funded balance sheet with ~\$6m in cash (as at end September 18), providing a ~2 year runway

Capital Structure & Financials		
Shares on Issue	128m	
Share Price (16 Nov-18)	\$0.155	
12-month Range	\$0.10 – \$0.28	
Market Cap	\$20m	
Cash Balance (Sep-18)	\$6m	



	Options Issued	Exercise Price	Expiry
Broker Options	2,000,000	20c	24/11/2020
Options*	25,056,730	20c	4/12/2018

^{*} Options were issued to all shareholders on a 1:5 basis pursuant to Prospectus dated 1/03/2018

BIO-GENE TECHNOLOGY